[go: up one dir, main page]

WO2008035208A3 - The use of polymethoxyflavones for the non apoptotic inhibition of cancer cell growth - Google Patents

The use of polymethoxyflavones for the non apoptotic inhibition of cancer cell growth Download PDF

Info

Publication number
WO2008035208A3
WO2008035208A3 PCT/IB2007/003174 IB2007003174W WO2008035208A3 WO 2008035208 A3 WO2008035208 A3 WO 2008035208A3 IB 2007003174 W IB2007003174 W IB 2007003174W WO 2008035208 A3 WO2008035208 A3 WO 2008035208A3
Authority
WO
WIPO (PCT)
Prior art keywords
polymethoxyflavones
differences
cancer cell
cancer
cell growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2007/003174
Other languages
French (fr)
Other versions
WO2008035208A2 (en
Inventor
Karen Morley
James Koropatnick
Najla Guthrie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KGK Synergize Inc
Original Assignee
KGK Synergize Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KGK Synergize Inc filed Critical KGK Synergize Inc
Publication of WO2008035208A2 publication Critical patent/WO2008035208A2/en
Anticipated expiration legal-status Critical
Publication of WO2008035208A3 publication Critical patent/WO2008035208A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Anticancer drug efficacy depends heavily on the differences in drug sensitivity between normal and neoplastic tissue While these differences in sensitivity are slim in the case of cytotoxic drugs causing cell death, cytostatic drugs that inhibit cellular proliferation arc not as dependent on the biochemical differences between cancer cells and normal cells The present invention is therefore directed to methods for the treatment of cancer, and inhibition of cancer cell proliferation without causing cell death, through the use of polymethoxyflavones The polymethoxyflavones tangeretin and nobiletin are particularly favoured for use in the present invention.
PCT/IB2007/003174 2006-05-19 2007-05-21 The use of flavonoids for the inhibition of cellular growth Ceased WO2008035208A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80168206P 2006-05-19 2006-05-19
US60/801,682 2006-05-19

Publications (2)

Publication Number Publication Date
WO2008035208A2 WO2008035208A2 (en) 2008-03-27
WO2008035208A3 true WO2008035208A3 (en) 2011-03-03

Family

ID=39200905

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/003174 Ceased WO2008035208A2 (en) 2006-05-19 2007-05-21 The use of flavonoids for the inhibition of cellular growth

Country Status (1)

Country Link
WO (1) WO2008035208A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9132117B2 (en) 2013-06-17 2015-09-15 Kgk Synergize, Inc Compositions and methods for glycemic control of subjects with impaired fasting glucose

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018523674A (en) * 2015-08-21 2018-08-23 ザ メソディスト ホスピタル Compositions and methods for selectively inhibiting intestinal carboxylesterase 2 enzyme activity
CN105147665A (en) * 2015-09-16 2015-12-16 华南理工大学 Application of tangeretin in preparation of medicine or health-care product for preventing and treating oral cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60199817A (en) * 1984-03-23 1985-10-09 Rikagaku Kenkyusho anticancer drug
WO2000019998A1 (en) * 1998-10-06 2000-04-13 Kgk Synergize Compositions and methods of inhibiting neoplastic diseases with compounds related to limocitrin and 5-desmethyl sinensetin
WO2000072862A1 (en) * 1999-06-01 2000-12-07 Ocean Spray Cranberries, Inc. Cranberry seed oil extract and compositions containing components thereof
WO2001021137A1 (en) * 1999-09-21 2001-03-29 Rutgers, The State University Extracts of orange peel for prevention and treatment of cancer
WO2001051043A2 (en) * 2000-01-12 2001-07-19 Kgk Synergize Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60199817A (en) * 1984-03-23 1985-10-09 Rikagaku Kenkyusho anticancer drug
WO2000019998A1 (en) * 1998-10-06 2000-04-13 Kgk Synergize Compositions and methods of inhibiting neoplastic diseases with compounds related to limocitrin and 5-desmethyl sinensetin
WO2000072862A1 (en) * 1999-06-01 2000-12-07 Ocean Spray Cranberries, Inc. Cranberry seed oil extract and compositions containing components thereof
WO2001021137A1 (en) * 1999-09-21 2001-03-29 Rutgers, The State University Extracts of orange peel for prevention and treatment of cancer
WO2001051043A2 (en) * 2000-01-12 2001-07-19 Kgk Synergize Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KANDASWAMI ET AL., CANCER LETTERS, vol. 56, February 1991 (1991-02-01), pages 147 - 152 *
KAWAII ET AL., BIOSCIENCE, BIOTECHNNOLOGY, AND BIOCHEMISTRY, vol. 63, May 1999 (1999-05-01), pages 896 - 899 *
MAK ET AL., LIFE SCIENCES, vol. 58, 1996, pages 1269 - 1276 *
MORLEY ET AL., CANCER LETTERS, vol. 251, 2 January 2007 (2007-01-02), pages 168 - 178 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9132117B2 (en) 2013-06-17 2015-09-15 Kgk Synergize, Inc Compositions and methods for glycemic control of subjects with impaired fasting glucose

Also Published As

Publication number Publication date
WO2008035208A2 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
BRPI0413427A (en) active pyridylpyrrole derivatives as kinase inhibitors
WO2008024978A3 (en) Tetrahydroindolone and tetrahydroindazolone derivatives
BRPI0416981A (en) compounds for treating cell proliferative diseases
CR9518A (en) ELIMINATION OF HETEROGENIC OR MIXED CELLULAR POPULATION IN TUMORS
WO2007098611A8 (en) Compositions for treatment of cancer
WO2006131649A3 (en) Use of fumagillin and the derivatives thereof to increase the bioavailability of the macrocyclic lactones
WO2004111192A3 (en) Targeted delivery to legumain-expressing cells
WO2006020048A3 (en) Compounds and methods for treatment of cancer
WO2009071480A3 (en) Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
MX2009006007A (en) Prodrugs and methods of making and using the same.
WO2006001956A3 (en) Compositions for inhibiting cell growth and inducing apoptosis in cancer cells and methods of use thereof
WO2008002460A3 (en) Orally available light-independent antineoplastic compounds
WO2009021971A3 (en) Novel targets and compounds for therapeutic intervention of hiv infection
WO2005118601A3 (en) Sulfonylethyl phosphorodiamidates for use in the treatment of cancer
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
UA102219C2 (en) Substotuted pyrazolo-quinazoline derivatives, process for the preparation and use thereof as kinase inhibitors
CL2008000495A1 (en) Compounds derived from tetrahydro-pyrazolo [4,3-c] pyridine; pharmaceutical composition; and use in the treatment of diseases such as allergies, inflammation, pain, cancer, among others.
MX2015003343A (en) TREATMENT COMBINED WITH THE NETRINA-1 INTERFERENCE PHARMACO AND THE CHEMOTHERAPEUTIC PHARMACO.
WO2008035208A3 (en) The use of polymethoxyflavones for the non apoptotic inhibition of cancer cell growth
WO2006131806A3 (en) Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
WO2005000204A3 (en) Pancreatic cancer treatment
WO2007027344A3 (en) Compounds and methods for the treatment of cancer
AU2002342808A1 (en) Extract with anti-tumor and anti-poisonous activity
WO2005076888A3 (en) Anti-cancer therapies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07848823

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07848823

Country of ref document: EP

Kind code of ref document: A2